China Oncology ›› 2022, Vol. 32 ›› Issue (1): 34-40.doi: 10.19401/j.cnki.1007-3639.2022.01.004

• Article • Previous Articles     Next Articles

Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma

LEI Kunyang1, XIE Wenjie1(), SUN Ting1, LIU Yifu1, WANG Xu2   

  1. 1. Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
    2. Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
  • Received:2021-10-07 Revised:2021-11-25 Online:2022-01-30 Published:2022-01-30
  • Contact: XIE Wenjie E-mail:doctorxiewenjie@163.com

Abstract:

Background and purpose: Long non-coding RNA (lncRNA) ARAP1-AS1 is abnormally expressed in a variety of tumors, but its role in clear cell renal cell carcinoma (ccRCC) is unknown. This study aimed to explore the biological role of ARAP1-AS1 in ccRCC. Methods: The expression level of ARAP1-AS1 in ccRCC tissues and its relationship to patient’s clinicopathological characteristics and survival rate were analyzed using the GEPIA database. The expression level of ARAP1-AS1 was measured in ccRCC and adjacent non-tumor tissues by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR). Patients were divided into ARAP1-AS1 high and low expression groups, the relationship between ARAP1-AS1 expression level and patient’s clinicopathological characteristics was analyzed, and survival analysis was performed. The effect of ARAP1-AS1 in vitro proliferation, migration and invasion ability of ccRCC cells was determined by cell counting kit-8 (CCK-8) assay, transwell migration and invasion assay. Changes in the expressions of Wnt/β-catenin signaling pathway-related proteins were detected by Western blot assay. The effect of ARAP1-AS1 on tumorigenic capacity in ccRCC cells in vivo was verified by tumor xenografts in nude mice. Results: The analysis of the GEPIA database showed that ARAP1-AS1 was highly expressed in ccRCC and associated with advanced tumor stage as well as poor survival in patients (all P<0.05). The results of RTFQ-PCR showed that ARAP1-AS1 was highly expressed in ccRCC tissues and cell lines, and high expression correlated with tumor size and stage (all P<0.05). The overall survival rate was poor in patients with high ARAP1-AS1 expression (P<0.05). Knockdown of ARAP1-AS1 expression inhibited the proliferation, migration and invasion of ccRCC cells (all P<0.05). Silencing of ARAP1-AS1 reduced the expression levels of the proteins involved in the Wnt/β-catenin signaling pathway (all P<0.05). Silencing of ARAP1-AS1 attenuated tumorigenic capacity in ccRCC cells and reduced Ki-67 proliferation index (P<0.05). Conclusion: ARAP1-AS1 promotes ccRCC progression through activation of the Wnt/β-catenin signaling pathway.

Key words: Clear cell renal cell carcinoma, ARAP1-AS1, Wnt/β-catenin

CLC Number: